Decoy Therapeutics Inc. (DCOY) AI Stock Analysis

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company based in Houston, Texas. Formerly known as Salarius Pharmaceuticals, Inc., the company changed its name to Decoy Therapeutics Inc. in January 2026. It focuses on advancing peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform. The platform leverages peptide coiled-coils chemistry, physics, machine learning, and artificial intelligence tools alongside synthesis techniques to engineer and manufacture peptide conjugates. Decoy Therapeutics concentrates on developing a therapeutic portfolio targeting unmet medical needs in infectious diseases and oncology.

Between FY2017 and FY2021, the company delivered a 5-year revenue CAGR of 12.7%. Annual revenue rose from $1.3M in FY2017 to $3.5M in FY2019 and peaked at $5.2M in FY2020, before dropping 64.8% to $1.8M in FY2021. Profitability remained negative over this timeframe, with net income recording -$34.4M in FY2017, -$7.4M in FY2020, and -$12.8M in FY2021, resulting in an FY2021 net margin of -693.8%. In the trailing twelve months ended June 30, 2026, revenue stood at $227,629, with an operating margin of -1055.8% and a profit margin of 0.0%, while diluted EPS was $12.74.

As of June 30, 2026, Decoy Therapeutics held $8.3M in cash and short-term investments, with total assets of $9.0M and shareholders' equity of $4.3M. The company maintained a current ratio of 1.83. Cash flow used in operations and free cash flow both stood at -$10.2M in FY2021. For FY2025, capital expenditures were $577,000. Additionally, the company's share count expanded by 3423.2% over a 5-year period.

Decoy Therapeutics has a market capitalization of $2.8M and an enterprise value of $344,923. The stock trades at a trailing price-to-earnings multiple of 0.1x, compared to the median of 24.6x for its US-listed Healthcare peers. Its price-to-sales ratio is 12.3x versus the peer median of 4.1x, while its EV-to-EBITDA stands at 1.5x against the sector median of 12.0x. Over the past year, the stock declined 97.7%, underperforming the S&P 500 benchmark return of 16.8%.

Wall Street coverage includes 1 Strong Buy rating, with 0 Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $3.00, representing a potential upside of 156.4% above the last close of $1.17 on October 16, 2026. For the current fiscal year ending December 31, 2026, consensus expectations project revenue of $0 and EPS of -$8.96. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is scheduled for November 13, 2026.

This page is an AI-written research summary of Decoy Therapeutics Inc. (DCOY). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DCOY income statement, DCOY balance sheet, DCOY key metrics, DCOY analyst forecast, DCOY chart. See the DCOY stock overview for the latest quote and news.